| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_034bfd56a60f64c13aedf7b0e71dead6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-829 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48969
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25136422e673512dcf25e3052bcec711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3131bf4aae74e2ff0bb05274b78b964e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4734b777c09c7762ee14775b2d390b28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_045b1ed7de3d7fe586e8bf4ed2008cbd |
| publicationDate |
2015-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015111838-A1 |
| titleOfInvention |
Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
| abstract |
This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. As well as cyclodextrin complexation methods of formulating a peptide proteasome inhibitor (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof) with one or more cyclodextrins. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. For example, homogenous solutions of a compound of formula (5) (carfilzomib) can be obtained at a pharmaceutically useful pH (e.g., about 3.5) and at higher concentrations (e.g., about 5 mg/mL) than could be obtained without one or more cyclodextrins and the processes of complexation between the compound and one or more cyclodextrins provided herein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11135311-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022159319-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018100434-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11491240-B2 |
| priorityDate |
2012-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |